Elutia (ELUT) Osake Kurssi

Aziyo Biologics Inc primarily operates in the healthcare and biotechnology industries.

The main competitors of Aziyo Biologics Inc in the market include Medtronic, Johnson & Johnson, Baxter International, and Zimmer Biomet. These companies also operate in the biologics and medical device industry, providing similar products and solutions. However, Aziyo Biologics Inc differentiates itself through its focus on the development and commercialization of regenerative medicine products, such as cardiovascular and orthopedic tissues. Aziyo Biologics Inc continues to strive for innovation and market presence, driving competition within the industry.

Aziyo Biologics Inc is a leading regenerative medicine company based in the United States. Established in 2015, the company specializes in the development and commercialization of innovative biologic products. Aziyo Biologics has a strong focus on creating solutions for surgical procedures within the fields of cardiovascular, orthopedics, and other medical specialties. With a commitment to improving patient outcomes, Aziyo Biologics combines cutting-edge science, advanced manufacturing techniques, and clinical expertise to deliver high-quality tissue products. The company's rich history of research, development, and collaboration with healthcare professionals has positioned it as a trusted provider in the regenerative medicine space.

Aziyo Biologics Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in March 2021, raising substantial funds to support its growth and business operations. Additionally, Aziyo Biologics has expanded its product portfolio by launching innovative regenerative medical solutions, including CanGaroo Envelope, a product designed to support cardiac implantable electronic devices. Furthermore, the company has established strategic partnerships with renowned healthcare organizations to enhance its market presence and broaden its customer base. Aziyo Biologics Inc continues to demonstrate its commitment to advancing the field of regenerative medicine through these notable achievements.

Aziyo Biologics Inc is primarily present in the United States.

Aziyo Biologics Inc represents a strong commitment to advancing the field of regenerative medicine and improving patient outcomes. Their corporate philosophy revolves around innovation, excellence, and collaboration. With a focus on developing and delivering high-quality tissue products and solutions, Aziyo Biologics aims to meet the diverse needs of the medical community. By leveraging their expertise, cutting-edge technology, and dedication to quality, the company strives to make a positive impact on the lives of patients worldwide. Aziyo Biologics also emphasizes transparency, integrity, and ethical practices, ensuring the utmost trust and confidence among their stakeholders.

7 analyytikkoa arvioi tällä hetkellä Elutia-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Elutia-yhtiöltä 7,50 M USD liikevaihtoa ja −0,57 USD osakekohtaista tulosta.

Elutia Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Elutia-osake noteerataan hintaan 0,71 EUR (0,79 USD).

Elutia-osake (ELUT) on listattuna 1 pörssissä, muun muassa: NASDAQ (AZYO).

Aziyo Biologics Inc is a company specializing in the development and marketing of cardiovascular and regenerative tissue products. It is headquartered in Silver Spring, Maryland, and has been in the market since 2015. The business model of Aziyo Biologics includes several divisions, including cardiovascular products, regenerative tissue technologies, and tissue banking services. The company's key products include the CanGaroo® PFO closure system, the BioBridge® vascular graft system, and the ViBone® regeneration product. The CanGaroo® PFO closure system is an innovative product designed specifically for closing defects in the interatrial septum. It is made from porcine tissue materials and is a safe and effective alternative to the transcutaneous PFO closure method. The BioBridge® vascular graft system is another important product of Aziyo Biologics. It is a synthetic vascular implant made from a biocompatible material and is an ideal choice for patients with spinal cord injuries or severe vascular complications. ViBone® is a regenerative product derived from clean donor bone and represents a natural source of growth factors. It is commonly used in repairing muscle and bone damage and is a key component of Aziyo's regenerative tissue solutions. To develop and distribute these products, Aziyo Biologics works closely with Aziyo Biologics Australia, a subsidiary specializing in the development of regenerative muscle and bone tissue. Additionally, the company operates a range of tissue banking services that allow patients to access donor tissue and improve their health. Aziyo Biologics' tissue banking services include preservation, processing, preparation, and storage of blood, bone, and other biological materials. These materials are then supplied to hospitals and medical facilities to support patients with injuries or illnesses. Aziyo Biologics' business model is based on creating high-quality tissue solutions and building long-term relationships with medical and health-related institutions. The company also conducts a range of research and development programs to create innovative new products and strengthen its presence in the market. Overall, Aziyo Biologics has established itself as a key player in the field of regenerative medicine and offers a wide range of products and services to help patients around the world. With a strong commitment to innovation and quality, the company has laid a solid foundation for future growth and progress.

odotettu liikevaihto Elutia on 7,50 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Elutia on −26,90 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Elutia:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,39. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Elutia-osakkeen arvostusta.

Elutia:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,00. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Elutia-osakkeen arvostuskennuslukuna.

Elutia:n Eulpool-laatuscore on 2/10.

Elutia:n ISIN on US05479K1060. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Elutia:n ticker on ELUT. Tämä pörssinoteeraus käytetään Elutia-osakkeiden kauppaan pörssissä.